Physician profile
Abdul Basit
NPI 1720081631
$5,140.53
in general payments reported to CMS, 2019-2025
28 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,579 · 2020: $238 · 2021: $347 · 2022: $1,427 · 2023: $323 · 2024: $556 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,200.00 | 2022 | |
| Boston Scientific Corporation | $601.07 | 2019-2022 | |
| Abbott Laboratories | $464.12 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $296.46 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $287.69 | 2022-2025 | Onpattro |
| Abiomed | $266.97 | 2019-2024 | Impella |
| Medtronic, INC. | $257.54 | 2023-2025 | Onyx Frontier, Hawkone, Ffrangio |
| Sanofi-Aventis U.S. LLC | $247.77 | 2019-2024 | |
| Endologix LLC | $238.81 | 2019 | |
| Shockwave Medical, INC | $210.02 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $182.61 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.56 | 2023-2025 | Lifevest |
| Genzyme Corporation | $125.00 | 2019 | |
| Amgen INC. | $123.39 | 2019-2025 | Repatha, Repatha |
| Cleerly, INC. | $122.41 | 2024 | Cleerly Ischemia, Cleerly Labs |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69.92 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $34.74 | 2021 | |
| Cook Medical LLC | $33.66 | 2022 | |
| Novo Nordisk INC | $32.20 | 2025 | Wegovy, Rybelsus, Ozempic |
| Inari Medical, INC. | $29.88 | 2020-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Elutia, INC. | $20.72 | 2022 | |
| Cardiovascular Systems INC. | $19.73 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $19.70 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $17.99 | 2022 | |
| Stryker Corporation | $17.97 | 2025 | Clottriever Bold Catheter |
| Tactile Systems Technology INC | $16.94 | 2023 | Entre Plus, Flexitouch Plus |
| Pfizer INC. | $14.40 | 2022 | |
| Scpharmaceuticals INC. | $14.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Basit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.